ENRICH _ Outcome relevance_Education content_240118.pptx

PSek 10 views 1 slides Jun 13, 2024
Slide 1
Slide 1 of 1
Slide 1
1

About This Presentation

CEA provides compelling evidence that MIPS is not only a cost-saving alternative but a more effective strategy for acute lobar supratentorial ICH. This dominance holds true in both the hospital and healthcare perspectives, challenging the conventional cost-effectiveness narrative in medical interven...


Slide Content

Economic Endpoint Discussion Rare Dominance in Effectiveness and Cost:  MIPS intervention stands out in the realm of neurological conditions, showcasing a rarity—being both more effective and less costly than the existing management strategy (MM). This dominance is observed from both the hospital and healthcare perspectives. Hospital Perspective Savings:  From the hospital perspective for lobar ICH, MIPS demonstrates a substantial cost advantage.  Healthcare Perspective Dominance:  as a dominant strategy with cost advantage coupled with a significant gain in Quality-Adjusted Life Years (QALY) MIPS emerges as the unequivocal dominant choice compared to MM. Unusual Cost-Effectiveness in Medical Interventions:  MIPS breaks the norm by being a cost-saving and more effective intervention. This contrasts with the common scenario where new medical interventions tend to cost more while offering increased effectiveness. MIPS challenges this trend, setting a unique precedent in the field of neurological conditions. Compelling Evidence for Adoption: In summary, this analysis provides compelling evidence that MIPS is not only a cost-saving alternative but a more effective strategy for acute lobar supratentorial ICH. This dominance holds true in both the hospital and healthcare perspectives, challenging the conventional cost-effectiveness narrative in medical interventions. The evidence strongly advocates for the widespread adoption of MIPS in treating this specific form of ICH, heralding a paradigm shift in neurological care.